PT  - JOURNAL ARTICLE
AU  - Stassen, Mario
AU  - Leitão, Catarina S.
AU  - Manzano, Toni
AU  - Valero, Francisco
AU  - Stevens, Benjamin
AU  - Schmucki, Matt
AU  - Hubmayr, David
AU  - Rubinat, Ferran Mirabent
AU  - Dessoy, Sandrine
AU  - Moreira, Antonio
TI  - Recommendations for Artificial Intelligence Application in Continued Process Verification: A Journey Toward the Challenges and Benefits of AI in the Biopharmaceutical Industry
AID  - 10.5731/pdajpst.2024.012950
DP  - 2025 Jan 01
TA  - PDA Journal of Pharmaceutical Science and Technology
PG  - 68--87
VI  - 79
IP  - 1
4099  - http://journal.pda.org/content/79/1/68.short
4100  - http://journal.pda.org/content/79/1/68.full
SO  - PDA J Pharm Sci Technol2025 Jan 01; 79
AB  - This review paper explores the transformative impact of Artificial Intelligence (AI) on Continued Process Verification (CPV) in the biopharmaceutical industry. Originating from the CPV of the Future project, the study investigates the challenges and opportunities associated with integrating AI into CPV, focusing on real-time data analysis and proactive process adjustments. The paper highlights the importance of aligning AI solutions with regulatory standards and offers a set of comprehensive recommendations to bridge the gap between AI's potential and its practical, compliant, and safe application in pharmaceutical manufacturing. Emphasizing transparency, interpretability, and risk management, the research contributes to establishing best practices for AI implementation, ensuring the highest quality pharmaceutical products while meeting regulatory expectations. The conclusions drawn provide valuable insights for navigating the evolving landscape of AI in pharmaceutical manufacturing. This paper serves as a guideline for implementing AI, Machine Learning and Deep Learning models to the pharma industry. Nevertheless, the specific algorithms used in the CPV of the Future are not relevant for our paper (Good Practices), since we have to generalize the process independent of the algorithm.